Home Compare GSK.L vs REC.MI
Stock Comparison · Industry comparison · Drug Manufacturers - General

GSK vs Recordati Industria Chimica e Farmaceutica S.p.A.: Which Stock Looks Stronger in 2026?

GSK holds the cleaner structural position, with the lead spread across valuation and stability. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The lead is spread across valuation and stability, rather than sitting in one isolated gap. The overall score gap is 13 points in favour of GSK plc.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. GSK.L and REC.MI share the same industry classification.

For a similarity-based comparison, see how GSK and REC.MI each position within their functional peer groups in AssetNext.

Peer-Relative Score
GSK.L
GSK plc
65
Peer-Score
Signal qualityHigh
vs
REC.MI
Recordati Industria Chimica e Farmaceutica S.p.A.
52
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: GSK.L vs REC.MI Profitability 46 46 Stability 69 44 Valuation 80 51 Growth 71 69 GSK.L REC.MI
Gap Ranking
#1 Valuation +29
#2 Stability +25
#3 Growth +2
#4 Profitability
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GSK.L and REC.MI Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GSK.LREC.MI Relative valuation Structural strength

GSK plc still looks stronger, and the price setup does not materially undermine that lead.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
Both rank well on valuation, but GSK plc still holds a clear edge.
Stability
On stability, the same pattern holds: both are strong, but GSK plc still leads clearly.
Valuation — Dominant Gap
GSK.L
80
REC.MI
51
Gap+29in favour of GSK.L

The multiple-based pricing edge comes from a forward P/E that is 2.6 turns lower.

What keeps the gap from being one-sided

Recordati Industria Chimica e Farmaceutica S.p.A. still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.

What this means for the comparison

The lead is built on both valuation and stability, making it broader than a single-dimension result.

Explore full peer positioning in AssetNext

Break down the GSK.L vs REC.MI comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-and-stability comparisons

Explore how GSK.L and REC.MI each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.